新型疗法角逐特应性皮炎领域,缘何上市后还要拼真实世界研究

第一财经
16 Apr

特应性皮炎(AD)是一种慢性、复发性、炎症性皮肤病,患者会出现剧烈瘙痒,严重影响生活质量,传统系统性药物因不良反应或疗效欠佳导致难以用于长期治疗。近年来,有越来越多的新型疗法,包括生物制剂及靶向小分子药物在内,正在进入这个疾病领域。  有意思的是,一些已获批上市的疗法,上市后还在加码真实世界研究,如何看待这种情况?  近期,在第83届美国皮肤科学会年会上,阿布昔替尼全球最大规模JAK1抑制剂...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10